-
07:00
-07:07
PARP inhibitor-induced senescence of cancer-associated fibroblasts drives CD8⁺T cell exhaustion and immunotherapy resistance in ovarian cancer
-
07:07
-07:14
EZH2 inhibition enhances checkpoint inhibitor blockade response in ovarian cancer
-
07:14
-07:21
Tumor–stroma proportion and survival in advanced ovarian cancer in the poly(ADP-ribose) polymerase inhibitor maintenance era
-
07:21
-07:28
Development of myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor therapy in patients with ovarian cancer
-
07:28
-07:35
Photothermal-responsive hydrogel microcapsules with programmable drug release for enhanced ovarian cancer therapy
-
07:35
-07:42
Targeting SIK2 initiates CD8+ T-cell immunity to enhance immunotherapy efficacy in ovarian cancer
-
07:42
-07:49
Combined cyclin-dependent kinase 7 and 9 inhibition induces functional homologous recombination deficiency and sensitizes ovarian cancer to poly (ADP-ribose) polymerase inhibition
-
07:49
-07:56
Efficacy of combination therapy with PARP inhibitors and immune checkpoint inhibitors in recurrent ovarian cancer: a systematic review and meta-analysis

